Free Trial
NASDAQ:KLDO

Kaleido Biosciences (KLDO) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
3,410 shs
Market Capitalization
$6.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
KLDO stock logo

About Kaleido Biosciences Stock (NASDAQ:KLDO)

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

KLDO Stock News Headlines

Kaleido Biosciences (OTC: KLDO)
Kaleido Biosciences Inc KLDO
IDXG Interpace Biosciences, Inc.
KLDO - Kaleido Biosciences, Inc.
See More Headlines
Receive KLDO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kaleido Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2021
Today
5/30/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:KLDO
Fax
N/A
Employees
76
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.10 million

Miscellaneous

Free Float
38,787,000
Market Cap
$4,000.00
Optionable
Not Optionable
Beta
-0.06
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Ms. Kimberly Hocknell
    Senior Vice President of Technical Operations
  • Dr. Mark A. Wingertzahn Ph.D. (Age 53)
    Senior VP of R&D and Head of Development

KLDO Stock Analysis - Frequently Asked Questions

How were Kaleido Biosciences' earnings last quarter?

Kaleido Biosciences, Inc. (NASDAQ:KLDO) announced its earnings results on Monday, November, 1st. The company reported ($0.54) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.54). The firm earned $0.10 million during the quarter, compared to analysts' expectations of $0.25 million.

What other stocks do shareholders of Kaleido Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), Fulcrum Therapeutics (FULC), LogicBio Therapeutics (LOGC), Homology Medicines (FIXX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE) and Stoke Therapeutics (STOK).

When did Kaleido Biosciences IPO?

Kaleido Biosciences (KLDO) raised $101 million in an initial public offering (IPO) on Thursday, February 28th 2019. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity was co-manager.

How do I buy shares of Kaleido Biosciences?

Shares of KLDO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KLDO) was last updated on 5/30/2024 by MarketBeat.com Staff

From Our Partners